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S110 Chronic Kidney DiseaseConclusion: The prevalence of hypertension in our inpatients was very
high. Most of the patients with hypertension were treated by two or
more types of antihypertensive drugs. The most frequently used antihyper-
tensive drug was CCB. Less than half of the patients used RASI to treat hy-
pertension and the control of hypertension was poor. But we improved the
situation of SBP and the up-to-standard rate of blood pressure by
hospitalization.http://dx.doi.org/10.1016/j.hkjn.2015.09.155
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Maosheng Chen, Yueming Liu, Juan Jin, Qiang He
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Hangzhou, Zhejiang, China
Objective: To assess the efficacy and safety of dipeptidyl peptidase-4
(DPP-4) inhibitors compared with placebo or with other hypoglycaemic
drugs in patients with type 2 diabetes mellitus and severe renal impair-
ment (RI).
Methods: A meta-analysis of RCTs was performed in adults with type 2 dia-
betes mellitus and severe RI, and assessed the comparative effect of DPP-4
inhibitors on HbA1C and fasting blood glucose (FPG). Safety was evaluated
based on analysis of percentage of hypoglycemia, occurrence of any adverse
events (AE) and any serious adverse events (SAE), the incidence of periph-
eral edema, urinary tract infection, diarrhea and death.
Results: Five RCTs and 503 patients were included. Compared with placebo
or no treatment, DPP-4 inhibitors were associated with a larger decline in
HbA1c (MD 0.57; 95% CI 0.73 to 0.41; P < 0.01) but not with FPG (MD
0.26; 95% CI 1.40 to 0.8; P Z 0.66). Compared with glipizide monother-
apy, no significant difference reached in HbA1c (MD 0.15; 95% CI 0.19 to
0.49; PZ 0.38) and FPG (MD 0.26; 95% CI 1.16 to 0.64; PZ 0.57). Similar
odds of any or serious adverse events between DPP-4 inhibitors and
comparators.
Conclusion: In type 2 diabetes mellitus and severe RI, treatment with DPP-4
inhibitors is safe and can effectively low HbA1c.http://dx.doi.org/10.1016/j.hkjn.2015.09.156
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Table 1 Multivariate analysis of different levels of eGFR associated with all
Baseline lev
 90
HR (95% Cl) p-value HR (95 %Cl)
Unadjusted Ref. 1.256 (1.156-1
Adjusted
Model 1 Ref. 0.959 (0.876-1
Model 2 Ref. 1.005 (0.916-1
Model 3 Ref. 1.051 (0.954-1
Model 4 Ref. 1.062 (0.946-1
Model 1: Adjusted for age, sex.
Model 2: Model 1+ BMI, HP, CVD, DM, smoking, drinking.
Model 3: Model 2 + ALB, ALT, AST, TG, GLU, hemoglobin, CRP.
Model 4: Model 3 + treatment (chemotherapy, surgery, combined treatment, b5Institute of Public Health, National Yang-Ming University, Kaohsiung,
Taiwan
Objective: Atrial fibrillation (AF) increases risk of thromboembolism events
and is prevalent among chronic kidney disease (CKD) patients. However, the
impact of AF on the mortality, acute coronary syndrome (ACS), and renal
function decline in CKD population are rare investigated. We determined
the association between incident AF and risk of death, cardiovascular
events, and end-stage renal disease (ESRD) among adults with CKD using na-
tional health insurance database in Taiwan.
Methods: CKD patients enrolled in the Pre-end stage renal disease (Pre-ESRD)
care management program,  18 years patients who were at least one outpa-
tient diagnosis codes (ICD-9 codes 585, 581.9) or at least one inpatient diagnosis
codes and free of any dialysis or renal transplant from Jan 1st 2007 to Dec 31st
2011 were included. CKD patients with AF were 1:5matched to control subjects
without AF by age, sex, urbanization, and socioeconomic status. Cox propor-
tional hazards regression models were used to estimate hazard ratios (HRs) for
all-cause mortality, cardiovascular events, and renal function decline analysis.
Results:Weincluded1995CKDpatientswithAF;of these,746 (37.4%)death,148
(7.4%)hadACS,222 (11.1%)had strokeor thromboembolism,and207 (10.4%)had
rapid eGFR decline. As compared with the CKD without AF subjects, those with
AFwasassociatedwithmultivariate-adjustedHRsof1.64 (95%CI, 1.49e1.81) for
death, 1.41 (95% CI, 1.14e1.74) for ACS, 2.15 (95% CI, 1.79e2.58) for stroke or
thromboembolism, 1.50 (95% CI, 1.31e1.73) for ESRD, and 3.35 (95% CI,
2.80e4.00) for rapid eGFR decline after adjusting comorbid disorders, clinical
characteristics, medications, and competing risk of mortality.
Conclusion: AF is independently associated with increased risk of developing
ACS, thromboembolism, and progression to ESRD in adults with CKD.http://dx.doi.org/10.1016/j.hkjn.2015.09.157
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Objective: To estimate the prevalence and the effect of abnormal renal
function in newly solid cancer patients.
Methods: From January 1, 2010 to December 31, 2010, 9128 patients with
newly diagnosed solid cancer in a cancer center were retrospectively stud-
ied. Renal function was calculated for each patients using Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula at the time of diag-
nosis. The prevalence of renal insufficiency (RI) and effect of RI on mortality
according to different treatments in these patients were investigated.
Results: Of the total 9128 patients, 31.7% had RI (eGFR < 90 ml/min/
1.73 m2), 2.9% had CKD (eGFR < 60 ml/min/1.73 m2), and 0.2% had
eGFR < 30 ml/min/1.73 m2. Patients with lymphoma and lung cancer have
the highest prevalence of CKD (4.3%, 4.1% respectively). Of the total pa-
tients, the number of patients who received treatment of surgery, chemo-
therapy, combination of surgery and chemotherapy, and best support care
(BSC) was 3131, 3110, 2035, 852, respectively. After multivariate analysis,
eGFR < 60 ml/min/1.73 m2 was found to be an independent risk factor for-cause mortality.
els of eGFR (ml/min/1.73m2)
60e89 <60
p-value HR (95% Cl) p-value
.365) <0.001 1.969 (1.630-2.379) <0 001
.049) 0.364 1.361 (1.121-1.653) 0.002
.103) 0.917 1.413 (1.155-1.729) 0.001
.158) 0.314 1.259 (1.021-1.553) 0.031
.171) 0.222 1.272 (1.031-1.570) 0.025
est supportive care).
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Table 2 HR of all-cause mortality according to levels of eGFR in different kinds of treatment cancer patients.
Baseline levels of eGFR (ml/min/1.73m2)
90 60-89 <60
HR (95%Cl) p-value HR (95%Cl) p-value HR (95%Cl) p-value
Best supportive care cancer patients
Unadjusted Ref. 1.073 (0.852-1.352) 0.548 2.203 (1.482-3.275) <0.001
Adjusted
Model 1 Ref. 0.753 (0.582-0.976) 0.032 1.448 (0.940-2.228) 0.093
Model 2 Ref. 0.848 (0.644-1.117) 0.241 1.567 (0.983-2.499) 0.059
Model 3 Ref. 1.125 (0.831-1.523) 0.445 1.637 (1.022-2.621) 0.040
Single treatment cancer patients
Chemotherapy
Unadjusted Ref. 1.260 (1.098-1.446) 0.001 2.546 (1.812-3.578) <0.001
Adjusted
Model 1 Ref. 0.985 (0.849-1.143) 0.843 1.619 (1.137-2.305) 0.008
Model 2 Ref. 1.022 (0.876-1.193) 0.779 1.586 (1.095-2.296) 0.015
Model 3 Ref. 1.117 (0.944-1.323) 0.198 1.671 (1.112-2.511) 0.014
Surgery
Unadjusted Ref. 1.181 (1.024-1.363) 0.023 1.350 (0.975-1.870) 0.071
Adjusted
Model 1 Ref. 0.961 (0.820-1.127) 0.625 1.056 (0.749-1.490) 0.755
Model 2 Ref. 1.010 (0.858-1.190) 0.901 1.068 (0.743-1.536) 0.721
Model 3 Ref. 1.078 (0.912-1.274) 0.377 0.967 (0.673-1.391) 0.858
Combined treatment cancer patients
Unadjusted Ref. 1.529 (1.264-1.849) <0.001 2.831 (1.781-4.500) <0.001
Adjusted
Model 1 Ref. 1.037 (0.845-1.272) 0.728 1.693 (1.050-2.729) 0.031
Model 2 Ref. 1.056 (0.859-1.298) 0.604 1.753 (1.083-2.836) 0.022
Model 3 Ref. 1.036 (0.837-1.283) 0.742 1.320 (0.763-2.283) 0.321
Model 1: Adjusted for age, sex.
Model 2: Model 1+ BMI, HP, CVD, DM, smoking, drinking.
Model 3: Model 2 + ALB, ALT, AST, TG, GLU, hemoglobin, CRP.
Chronic Kidney Disease S111all-cause mortality (HR Z 1.272; 95% CI, 1.031e1.570; p Z 0.025). On sub-
group analysis, for patients received surgery, combination treatment,
eGFR < 60 ml/min/1.73 m2 was not an independent risk factor for all-cause
mortality, however, it was an independent risk factor for patients who
received chemotherapy (HR Z 1.671; 95% CI, 1.112e2.511; p Z 0.014) or
BSC (HR Z 1.637; 95% CI, 1.022e2.621; p Z 0.040).
Conclusion: RI appears frequently for patients with newly diagnosed solid
cancer. eGFR < 60 ml/min/1.73 m2 is an independent risk factor for all-
cause mortality, but for patients who received different treatments, its in-
fluence on death works differently.http://dx.doi.org/10.1016/j.hkjn.2015.09.158
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Objective: Established the animal model of early stage of CKD and
detection whether the vascular calcification is happened. Then
investigated the relationship between vascular calcification and oxidative
stress.
Methods: 6 male 10 weeks SD rats fed with chow containing 0.75% adenine,
0.25% protein, 1.06% calcium and 0.92% phosphorus. Collect the 24-hour
urine and serum in weeks 0, 2, 3 and 4 to measure creatinine clearance
rate. 32 male 11 weeks SD rat, collect the 24-hour urine and randomly
divided into normal group, contrast feeding group, model group and treat-
ment group. The latter two groups were fed with chow above-mentioned.
Give the MnTMPyP 30 nmol per day intraperitoneally to treatment group.
The other two groups were fed with standardized chow containing the
same calcium and phosphorus. Make the intake of contrast feeding group
same with model group. After 4 weeks, anesthetize the rats collect blood
and 24-hour urine to measure serum biochemical parameters and 8-OHdG
in ELISA. Collect aortas to measure Von Kossa staining and calcium content
assay. Runx2, SM22a were measured in western blot.Results: The kidney of model group and treatment group appeared as “big
white kidney”. The cortex tend to thin and the demarcation of medulla is
unclear. The glomerulus atrophy and a lot of black crystal deposited on
the renal interstitium and lymphocyte infiltrated in the interstitium. Also
the creatinine increased and creatinine clearance decreased significantly
(p < 0.01). And accord with the standard of early CKD in rats. And the hypo-
calcemia and hyperphosphatemia are significantly too (p < 0.01). 8-OHdG,
calcium content and calcification increased significantly and treatment
group has a downward trend. The expression of SM22a significant descreased
while Runx2 is increased.
Conclusion: CKD-MBD have already occurred in early stage of CKD. Phosphorus
and oxidative stress participated in the vascular calcification and the phenotype
transdifferentiation of VSMCs is the principal reason in it.http://dx.doi.org/10.1016/j.hkjn.2015.09.159
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Waist-to-hip Ratio is Associated with Chronic Kidney Disease
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Objective: To evaluate the association between the anthropometric indices
of obesity and CKD and investigate the predictive value of waist-to-hip
circumference on CKD.
Methods: A total of 346 participants were enrolled in this study from January
2012 to August 2014 in General Hospital of Ningxia Medical University,
including 167 patients with CKD and 179 patients of healthy people as the
control group. Indices of obesity included body mass index, waist circumfer-
ence and waist-to-hip ratio (WHR). A multivariate logistic regression model
was used to analyze the associations between CKD and its risk factors with
the anthropometric indices of obesity. Receiver operating characteristic
(ROC) curves make further to explore the predictive value of various indices
of obesity on CKD.
Results: (1) The mean age of CKD patients (99 male and 68 female) was
38.0  8.7 years while the mean age of healthy control group (92 male
and 87 female) was 36.3  8.5 years. (2) The significant higher level of
